News Room
News Room
News Room
Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study
Topline data from Phase 3 study in patients with Tourette syndrome shows statistical significance between ecopipam and placebo for both the primary efficacy endpoint [...]
Emalex Biosciences Named “Neuroscience Therapeutics Company Of The Year” by BioTech Breakthrough
Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industries CHICAGO, November 19, 2024 – Emalex Biosciences was named “Neuroscience [...]
Article Highlights Positive Study Results Presented at AAN Annual Meeting
By Mary Beth Nierengarten, April 1, 2024 – Ecopipam reduced the number of tics and the level of daily interference they cause in children [...]
Harmony Biosciences Ranked Among Top 25 Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500™
Ranking attributed to 7,204% growth from fiscal year 2019 to 2022 PLYMOUTH MEETING, Pa., Nov. 15, 2023 /PRNewswire/ – Harmony Biosciences Holdings, Inc. ("Harmony" [...]
Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development
New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches CHICAGO - BUSINESS WIRE, September 27, 2023 – Evozyne [...]
Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc.
Acquisition expands pipeline and diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs [...]
